Investor Presentaiton
Novo Nordisk Annual Report 2023
PERFORMANCE HIGHLIGHTS
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
8
Our strategy execution progress
Purpose and
sustainability
Strategic Aspirations 2025
Progress towards zero environmental impact
Being respected for adding value to society
Further raise the innovation-bar for diabetes treatment
Innovation and
therapeutic focus
Being recognised as a sustainable employer
☑
Commercial
execution
Financials
Develop a leading portfolio of superior treatment solutions for obesity
Strengthen and progress the Rare Disease pipeline
Establish presence in Cardiovascular & Emerging Therapy Areas focusing on CVD, MASH and CKD
Strengthen diabetes leadership - aim at global value market share of more than 1/3
More than DKK 25 billion in Obesity sales by 2025
Secure a sustained growth outlook for Rare Disease
Deliver solid sales and operating profit growth
Drive operational efficiencies across the value chain to enable investments in future growth assets
Deliver free cash flow to enable attractive capital allocation to shareholders
Progress
Carbon emissions from operations and transportation decreased by 34% compared to 2019 (decreased by 8% compared to 2022)
Medical treatment provided to 40.5 million people living with diabetes
Reached more than 52,000 children in Changing Diabetes in Children programme
Human insulin with more flexible storage without refrigeration now approved in 29 countries
Partnership with Aspen to produce human insulin for people living with diabetes in Africa
Share of women in senior leadership positions has increased to 41% from 39% in 2022
Regulatory submission of once-weekly insulin icodec in the EU, the US and China
Successful completion of phase 3 trial with higher doses of oral semaglutide
Initiation of phase 3a trial with CagriSema in type 2 diabetes
FLOW kidney outcomes trial stopped based on interim analysis due to efficacy
Successful completion of phase 3 trial with IcoSema
• Successful completion of phase 3 trial with 50 mg of oral semaglutide
Successful completion of SELECT cardiovascular outcomes trial
• Successful completion of STEP HFPEF phase 3 trials
Acquisition of Inversago Pharma and phase 2 trial initiated with INV-202 and phase 1 trial initiated with INV-347
• Successful completion of phase 1 trial with oral amycretin
• Somapacitan approved in the US, EU and Japan for the treatment of growth hormone deficiency in children
Phase 1 trials initiated with cell therapy treatment in heart failure and Parkinson's disease
Acquisition of ocedurenone for the treatment of hypertension
Phase 1 trial initiated with ANGPTL3i mAb
Phase 1 trial initiated with VAP-1i in MASH
Diabetes value market share increased by 1.9 percentage points to 33.8% (MAT)
Obesity care sales increased by 154% (CER) to DKK 41.6 billion
Rare disease sales decreased by 15% (CER) to DKK 17.2 billion
Sales growth of 36% (CER)
Operating profit growth of 44% (CER)
Operational leverage reflecting sales growth
Free cash flow of DKK 68.3 billion.
DKK 61.7 billion returned to shareholdersView entire presentation